CRL vs. DGX: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at CRL and DGX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | CRL | DGX |
|---|---|---|
| Company Name | Charles River Laboratories International, Inc. | Quest Diagnostics Incorporated |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Health Care Providers & Services |
| Market Capitalization | 8.73 billion USD | 20.05 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | June 23, 2000 | December 17, 1996 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of CRL and DGX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | CRL | DGX |
|---|---|---|
| 5-Day Price Return | 20.64% | -5.04% |
| 13-Week Price Return | 12.86% | 1.36% |
| 26-Week Price Return | 17.81% | 5.99% |
| 52-Week Price Return | -8.07% | 15.80% |
| Month-to-Date Return | 13.34% | -5.90% |
| Year-to-Date Return | -3.94% | 18.87% |
| 10-Day Avg. Volume | 1.09M | 0.92M |
| 3-Month Avg. Volume | 0.89M | 0.95M |
| 3-Month Volatility | 46.53% | 24.54% |
| Beta | 1.62 | 0.64 |
Profitability
Return on Equity (TTM)
CRL
-2.01%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.51%
- Median
- 6.47%
- Q1
- 3.86%
- Min
- -6.95%
CRL has a negative Return on Equity of -2.01%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
DGX
13.70%
Health Care Providers & Services Industry
- Max
- 24.86%
- Q3
- 15.79%
- Median
- 8.56%
- Q1
- 5.75%
- Min
- -1.64%
DGX’s Return on Equity of 13.70% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
CRL
-1.72%
Life Sciences Tools & Services Industry
- Max
- 32.18%
- Q3
- 18.30%
- Median
- 10.19%
- Q1
- 4.20%
- Min
- -2.05%
CRL has a negative Net Profit Margin of -1.72%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
DGX
9.03%
Health Care Providers & Services Industry
- Max
- 11.56%
- Q3
- 5.45%
- Median
- 2.83%
- Q1
- 1.13%
- Min
- -1.71%
A Net Profit Margin of 9.03% places DGX in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
CRL
3.09%
Life Sciences Tools & Services Industry
- Max
- 38.39%
- Q3
- 21.40%
- Median
- 13.57%
- Q1
- 8.38%
- Min
- -3.51%
CRL’s Operating Profit Margin of 3.09% is in the lower quartile for the Life Sciences Tools & Services industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
DGX
14.02%
Health Care Providers & Services Industry
- Max
- 19.08%
- Q3
- 9.66%
- Median
- 4.77%
- Q1
- 2.46%
- Min
- -0.83%
An Operating Profit Margin of 14.02% places DGX in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | CRL | DGX |
|---|---|---|
| Return on Equity (TTM) | -2.01% | 13.70% |
| Return on Assets (TTM) | -0.90% | 5.94% |
| Net Profit Margin (TTM) | -1.72% | 9.03% |
| Operating Profit Margin (TTM) | 3.09% | 14.02% |
| Gross Profit Margin (TTM) | 35.03% | 33.23% |
Financial Strength
Current Ratio (MRQ)
CRL
1.36
Life Sciences Tools & Services Industry
- Max
- 3.46
- Q3
- 2.78
- Median
- 1.91
- Q1
- 1.53
- Min
- 0.43
CRL’s Current Ratio of 1.36 falls into the lower quartile for the Life Sciences Tools & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
DGX
1.09
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.51
- Median
- 1.29
- Q1
- 0.92
- Min
- 0.14
DGX’s Current Ratio of 1.09 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
CRL
0.70
Life Sciences Tools & Services Industry
- Max
- 1.35
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
CRL’s Debt-to-Equity Ratio of 0.70 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
DGX
0.78
Health Care Providers & Services Industry
- Max
- 2.29
- Q3
- 1.24
- Median
- 0.74
- Q1
- 0.50
- Min
- 0.00
DGX’s Debt-to-Equity Ratio of 0.78 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
CRL
1.71
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
In the lower quartile for the Life Sciences Tools & Services industry, CRL’s Interest Coverage Ratio of 1.71 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
DGX
7.42
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.50
- Median
- 4.52
- Q1
- 2.12
- Min
- -4.44
DGX’s Interest Coverage Ratio of 7.42 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | CRL | DGX |
|---|---|---|
| Current Ratio (MRQ) | 1.36 | 1.09 |
| Quick Ratio (MRQ) | 0.96 | 0.86 |
| Debt-to-Equity Ratio (MRQ) | 0.70 | 0.78 |
| Interest Coverage Ratio (TTM) | 1.71 | 7.42 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
CRL
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.41%
- Q3
- 0.65%
- Median
- 0.35%
- Q1
- 0.00%
- Min
- 0.00%
CRL currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
DGX
1.70%
Health Care Providers & Services Industry
- Max
- 5.93%
- Q3
- 2.59%
- Median
- 1.35%
- Q1
- 0.00%
- Min
- 0.00%
DGX’s Dividend Yield of 1.70% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
CRL
0.00%
Life Sciences Tools & Services Industry
- Max
- 113.14%
- Q3
- 61.34%
- Median
- 17.74%
- Q1
- 0.00%
- Min
- 0.00%
CRL has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
DGX
36.00%
Health Care Providers & Services Industry
- Max
- 185.33%
- Q3
- 74.82%
- Median
- 36.00%
- Q1
- 0.00%
- Min
- 0.00%
DGX’s Dividend Payout Ratio of 36.00% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | CRL | DGX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.70% |
| Dividend Payout Ratio (TTM) | 0.00% | 36.00% |
Valuation
Price-to-Earnings Ratio (TTM)
CRL
--
Life Sciences Tools & Services Industry
- Max
- 75.35
- Q3
- 51.00
- Median
- 32.93
- Q1
- 25.27
- Min
- 1.43
P/E Ratio data for CRL is currently unavailable.
DGX
21.13
Health Care Providers & Services Industry
- Max
- 40.02
- Q3
- 29.75
- Median
- 21.09
- Q1
- 14.18
- Min
- 7.05
DGX’s P/E Ratio of 21.13 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
CRL
2.20
Life Sciences Tools & Services Industry
- Max
- 10.49
- Q3
- 6.43
- Median
- 4.66
- Q1
- 2.88
- Min
- 1.08
In the lower quartile for the Life Sciences Tools & Services industry, CRL’s P/S Ratio of 2.20 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
DGX
1.91
Health Care Providers & Services Industry
- Max
- 3.15
- Q3
- 1.87
- Median
- 0.74
- Q1
- 0.27
- Min
- 0.09
DGX’s P/S Ratio of 1.91 is in the upper echelon for the Health Care Providers & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
CRL
2.22
Life Sciences Tools & Services Industry
- Max
- 6.69
- Q3
- 5.00
- Median
- 3.46
- Q1
- 2.38
- Min
- 0.93
CRL’s P/B Ratio of 2.22 is in the lower quartile for the Life Sciences Tools & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
DGX
2.77
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.45
- Median
- 2.52
- Q1
- 1.15
- Min
- 0.66
DGX’s P/B Ratio of 2.77 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | CRL | DGX |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 21.13 |
| Price-to-Sales Ratio (TTM) | 2.20 | 1.91 |
| Price-to-Book Ratio (MRQ) | 2.22 | 2.77 |
| Price-to-Free Cash Flow Ratio (TTM) | 15.29 | 16.40 |